Table 4

Internal responsiveness of disease activity measures in patients with primary Sjögren's syndrome treated with rituximab

Standardised response mean
Time point	ESSPRI	ESSDAI	Patient's GDA	Physician's GDA	IgM-Rf	SWS
Week 16	−0.86	−1.19	−0.97	−2.41	−0.80	0.25
Week 24	−0.68	−0.98	−0.73	−2.62	−0.78	0.24
Week 36	−0.53	−0.99	−0.94	−1.99	−0.65	0.10
Week 48	−0.27	−0.34	−0.83	−1.24	−0.20	0.18
Week 60	−0.29	−0.04	−0.49	−0.66	0.10	−0.13

Effect size
Time point	ESSPRI	ESSDAI	Patient's GDA	Physician's GDA	IgM-Rf	SWS
Week 16	−0.77	−1.13	−1.21	−2.36	−0.48	0.15
Week 24	−0.66	−1.11	−0.90	−2.65	−0.48	0.19
Week 36	−0.55	−1.13	−1.22	−2.41	−0.29	0.09
Week 48	−0.25	−0.60	−0.99	−1.78	−0.08	0.11
Week 60	−0.28	−0.05	−0.65	−1.01	0.09	−0.09

ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity assessment; IgM-Rf, rheumatoid factor; SWS, stimulated whole salivary flow.